2025 Neurotech Review: BCIs, Brain Delivery, Organoids and Neuro-AI Move Closer to Clinic
Forward signals for 2026—from >$1.3B in tracked financings led by Neuralink’s $650M round to a shoebox-sized biocomputer, driven device control, speech restoration, and early clinical proof points.
As we step into 2026, let’s look back at how neurotech unfolded over the past year. In 2025, neurotechnology broadened and sped up across multiple fronts. BCIs, brain-targeted delivery, neurodiagnostics, organoids, and neuro-focused AI all saw more activity moving from concept work into larger studies, bigger datasets, and concrete development plans, with sizable Series A-D rounds backing specific bets on CNS biology.
To read the rest of this article, upgrade to a BiopharmaTrend Pro subscription.
Gain full access to all of our deep dives and content archives.
Already a member? Sign in here.
